Quadrature Capital’s Spero Therapeutics SPRO Stock Holding History

Quadrature Capital’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40,128	Closed	-$93.9K	–	2026
2026 Q1	$93.9K	Buy	40,128 +2,329	+6%	+$5.53K	﹤0.01%	1232
2025 Q4	$88.1K	Buy	+37,799	New	+$87.8K	﹤0.01%	1123
2025 Q3	–	Sell	-31,205	Closed	-$90.5K	–	1460
2025 Q2	$90.5K	Buy	+31,205	New	+$44.9K	﹤0.01%	899

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadrature Capital's SPRO Position: Q2 2026 in Review

Quadrature Capital sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 40,128 shares — an estimated $93.9K sold.

Quadrature Capital first reported a position in SPRO in Q2 2025 and held it in 3 quarters. The position peaked at $93.9K in Q1 2026. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Quadrature Capital reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 40,128 Spero Therapeutics shares in Q2 2026, an estimated $93.9K.
Quadrature Capital first reported a position in Spero Therapeutics in Q2 2025 and held it in 3 quarters.
Quadrature Capital's Spero Therapeutics position peaked at $93.9K in Q1 2026.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.